Bio-Rad Q2 Beat Masks Revenue Decline
Bio-Rad Laboratories posted Q2 earnings per share of $2.62, beating consensus by 49.9%, but much of the gain came from a fair-value increase in its Sartorius equity stake rather than core operations.
Bio-Rad Q2 Beat Masks Revenue Guidance Slide
NEW YORK, October 17 —
Bio-Rad Laboratories, Inc. (BIO) posted Q2 2026 non-GAAP EPS of $2.62, beating the consensus by 49.9% after back-to-back misses. The headline number obscures an operational picture where revenue is contracting, margins remain below year-ago levels, and the stock has already run well past the price at which management was buying it just three months ago.
- Non-GAAP EPS $2.62 beat consensus by 49.9%; GAAP net income $371.4M primarily reflects a Sartorius stake fair-value gain.
- Full-year 2026 guidance: currency-neutral revenue decline of 3.0% to growth of 0.5%; non-GAAP operating margin 10% to 12%.
- Stock at $353.70, 36.3x forward P/E, above $335 analyst consensus target and 25% above Q2 buyback price.
The Beat That Sartorius Built
The 49.9% EPS beat looks different once the components are separated. Bio-Rad's non-GAAP net income was $70.2 million; the GAAP figure of $371.4 million was driven primarily by a fair-value gain on its Sartorius AG equity stake (a bioprocessing equipment maker), not by operating performance. Life Science, which supplies protein-separation instruments to pharmaceutical and biotech manufacturers, fell 5.1% currency-neutral to $252 million on academic research softness. Clinical Diagnostics, which makes quality controls and blood-typing systems for hospital labs, grew just 0.3% currency-neutral to $399 million. The prior two quarters had missed consensus by 7.0% and 5.0%.
Bought at $281, Trading at $353
That gap between buyback price and current price is the valuation puzzle. Bio-Rad repurchased 110,000 shares at an average of $281.57 in Q2, a price management apparently found attractive; the stock now sits at $353.70, above the $335 analyst consensus target, at a 36.3x forward P/E on trailing twelve-month revenue that has contracted 0.1%. CEO Norman Schwartz described the company's engagement with Elliott Management as 'active, I would say, constructive dialogue,' with apparent alignment on capital allocation. The Sartorius AG stake, which Schwartz described only as 'monetizable at the right time and price,' is the asset the market appears to be pricing ahead of the underlying business.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| BIO | $9.5B | 36.3x | +13.3% |
| MTD | $32.5B | 31.3x | +20.8% |
| CRL | $14.3B | 23.5x | +66.3% |
| WST | $27.0B | 38.5x | +39.3% |
| TFX | $5.5B | 11.9x | -1.8% |
| TECH | $11.4B | 31.4x | +16.0% |
What November 4 Needs to Show
Q3 results arrive November 4. The two variables that matter most are China, where high-teens revenue declines were attributed to order timing rather than structural demand, and where new in-China manufacturing now qualifies Bio-Rad for local government tenders, and margin recovery. Non-GAAP operating margin reached 12.5% in Q2, recovering from 6.6% in Q1 but still below the 13.6% of Q2 2025; full-year guidance of 10% to 12% leaves little room to spare. A $90 million restructuring program targets $30 million to $35 million in annualized savings by end of 2027. Digital PCR instrument revenue grew more than 20% in Q2, a point of real momentum entering the second half. Run the free Bio-Rad Laboratories, Inc. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Did Bio-Rad beat earnings expectations in Q2?
Yes. Bio-Rad posted non-GAAP EPS of $2.62, beating consensus by 49.9% after back-to-back misses in prior quarters. However, the GAAP net income of $371.4 million was primarily driven by a fair-value gain on the company's Sartorius stake, not by core operations.
Why did Bio-Rad's EPS beat look different than expected?
The company's non-GAAP net income was only $70.2 million. The much larger GAAP figure of $371.4 million was driven by a fair-value gain on Bio-Rad's Sartorius AG equity stake, a bioprocessing-equipment investment, not underlying business results.
How is Bio-Rad's core business performing?
Both operating segments showed weakness. Life Science revenue fell 5.1% currency-neutral to $252 million on academic research softness, while Clinical Diagnostics grew just 0.3% currency-neutral to $399 million. Full-year guidance projects currency-neutral revenue decline of 3.0% to growth of 0.5%.
What's the valuation story for Bio-Rad stock?
The stock trades at $353.70, a 36.3x forward P/E, above the $335 analyst consensus target. Bio-Rad repurchased 110,000 shares at $281.57 in Q2; the current price reflects a significant run-up from that buyback level, suggesting the market is pricing the Sartorius stake ahead of the underlying business.
What's the next catalyst for Bio-Rad?
Q3 results arrive November 4. The most important variables are China (where management attributed high-teens revenue declines to order timing rather than structural demand) and margin recovery. Non-GAAP operating margin reached 12.5% in Q2, recovering from 6.6% in Q1 but still below the 13.6% of Q2 2025.
Bio-Rad Laboratories posted Q2 2026 non-GAAP EPS of $2.62 — a 49.9% beat against the consensus estimate — yet guided full-year revenue to decline as much as 3% while launching a $90 million restructuring program. With Q3 results due November 4 and the stock trading above analyst targets at 36.3x forward P/E, investors must reconcile a headline earnings surprise with an operational picture that has not yet turned.